TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Summary

The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with the GSK AS03B adjuvant and tetravalent dengue live attenuated virus (TDENV-LAV) vaccine Formulation 17 (F17) will gather data to help better understand the human immune response to dengue vaccination and infection. This study is being done to evaluate the safety and immune reaction of administering one dose of dengue purified inactivated vaccine and one dose of dengue live attenuated vaccine compared to two doses of inactivated vaccine.

Timeline

Start

2016-01

Primary completion

2017-04

Completion

2018-04

Outcome

Outcome not reported

Stopped: “lack of materials, not moving forward”

Drugs

Indications